Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 239

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition

Open access
Gallo, David, Young, Jordan T. F., Fourtounis, Jimmy, Martino, Giovanni, Álvarez-Quilón, Alejandro, Bernier, Cynthia, Duffy, Nicole M., Papp, Robert, Roulston, Anne, Stocco, Rino, Szychowski, Janek, Veloso, Artur, Alam, Hunain, Baruah, Prasamit S., Fortin, Alexanne Bonneau, Bowlan, Julian, Chaudhary, Natasha, Desjardins, Jessica, Dietrich, Evelyne, Fournier, Sara, Fugère-Desjardins, Chloe, Goullet de Rugy, Theo, Leclaire, Marie-Eve, Liu, Bingcan, Bhaskaran, Vivek, Mamane, Yael, Melo, Henrique, Nicolas, Olivier, Singhania, Akul, Szilard, Rachel K., Tkáč, Ján, Yin, Shou Yun, Morris, Stephen J., Zinda, Michael, Marshall, C. Gary, Durocher, Daniel · 2022 · Nature

Abstract

Amplification of the CCNE1 locus on chromosome 19q12 is prevalent in multiple tumour types, particularly in high-grade serous ovarian cancer, uterine tumours and gastro-oesophageal cancers, where high cyclin E levels are associated with genome instability, whole-genome doubling and resistance to cytotoxic and targeted therapies 1–4 . To uncover therapeutic targets for tumours with CCNE1 amplification, we undertook genome-scale CRISPR–Cas9-based synthetic lethality screens in cellular models of CCNE1 amplification. Here we report that increasing CCNE1 dosage engenders a vulnerability to the inhibition of the PKMYT1 kinase, a negative regulator of CDK1. To inhibit PKMYT1, we developed RP-6306, an orally bioavailable and selective inhibitor that shows single-agent activity and durable tumour regressions when combined with gemcitabine in models of CCNE1 amplification. RP-6306 treatment causes unscheduled activation of CDK1 selectively in CCNE1- overexpressing cells, promoting early mitosis in cells undergoing DNA synthesis. CCNE1 overexpression disrupts CDK1 homeostasis at least in part through an early activation of the MMB–FOXM1 mitotic transcriptional program. We conclude that PKMYT1 inhibition is a promising therapeutic strategy for CCNE1 -amplified cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-022-04638-9

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 239

Metadata

Authors
Gallo, D., Young, J. T. F., Fourtounis, J., Martino, G., Álvarez-Quilón, A., Bernier, C., Duffy, N. M., Papp, R., Roulston, A., Stocco, R., Szychowski, J., Veloso, A., Alam, H., Baruah, P. S., Fortin, A. B., Bowlan, J., Chaudhary, N., Desjardins, J., Dietrich, E., Fournier, S., Fugère-Desjardins, C., Goullet de Rugy, T., Leclaire, M.-E., Liu, B., Bhaskaran, V., Mamane, Y., Melo, H., Nicolas, O., Singhania, A., Szilard, R. K., Tkáč, J., Yin, S. Y., Morris, S. J., Zinda, M., Marshall, C. G., & Durocher, D.
Venue
Nature
Published
2022-04-20
Volume
604
Issue
7907
Pages
749-756
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4225297234
Cited by
239
References
9
FWCI
16.40
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. https://app.cochat.ai/papers/10.1038/s41586-022-04638-9
The paper
Gallo, D., Young, J. T. F., Fourtounis, J., Martino, G., Álvarez-Quilón, A., Bernier, C., Duffy, N. M., Papp, R., Roulston, A., Stocco, R., Szychowski, J., Veloso, A., Alam, H., Baruah, P. S., Fortin, A. B., Bowlan, J., Chaudhary, N., Desjardins, J., Dietrich, E., . . . Durocher, D. (2022). CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature. https://doi.org/10.1038/s41586-022-04638-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.